The short version of peptide research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
This tells us how much the plane of polarization is rotated when the ray of light passes through a specific amount of optically active molecules of a sample. Therefore, the optical rotation depends on temperature, concentration, wavelength, path length, and the substance being analyzed.
suborder Clypeasterina family Clypeasteridae L. Agassiz, 1835 family Fossulasteridae Philip & Foster, 1971 † family Scutellinoididae Irwin, 1995 † family Conoclypeidae von Zittel, 1879 † family Faujasiidae Lambert, 1905 † family Oligopygidae Duncan, 1889 † family Plesiolampadidae Lambert, 1905 † suborder Scutellina infraorder Laganiformes family Echinocyamidae Lambert & Thiéry, 1914 family Fibulariidae Gray, 1855 family Laganidae Desor, 1858 infraorder Scutelliformes family Echinarachniidae Lambert in Lambert & Thiéry, 1914 family Eoscutellidae Durham, 1955 † family Protoscutellidae Durham, 1955 † family Rotulidae Gray, 1855 superfamily Scutelloidea Gray, 1825 family Abertellidae Durham, 1955 † family Astriclypeidae Stefanini, 1912 family Dendrasteridae Lambert, 1900 -- Pacific eccentric sand dollar. family Mellitidae Stefanini, 1912 -- Keyhole sand dollars family Monophorasteridae Lahille, 1896 † family Scutasteridae Durham, 1955 † family Scutellidae Gray, 1825 family Taiwanasteridae Wang, 1984 family Scutellinidae Pomel, 1888a † However, the traditional Clypeasteroida is currently not thought to represent a monophyletic group because the Clypeasterina and Scutellina are most likely not each other's closest relatives. Their similarities are possibly the result of convergent evolution. They are part of clade Luminacea, which also includes the orders Cassiduloida and Echinolampadoida. In a recent classification, Clypeasteroida includes only the former Clypeasterina.
As a result of population growth in African-Caribbean regions of overseas France and immigration from North and sub-Saharan Africa to mainland France, sickle cell disease has become a major health problem in France. Sickle cell disease has become the most common genetic disease in the country, with an overall birth prevalence of one in 2,415 in mainland France, ahead of phenylketonuria (one in 10,862), congenital hypothyroidism (one in 3,132), congenital adrenal hyperplasia (one in 19,008) and cystic fibrosis (one in 5,014) for the same reference period.
Sources: en.wikipedia.org
==== Larva ==== Cabbage looper larvae are a type of cabbage worm, green in colour with a white stripe on the side. After hatching, they are green and slightly hairy, but eventually turn green and lose the hair, leaving only a few bristles. They are identified by their looping behaviour, in which they arch their body in a loop when they crawl. Larvae are generally 3–4 cm long, and can have four to seven instars within 9–14 days. Larvae initially do not consume much food but increase their consumption during their lifetime until they are consuming three times their weight daily.
== Production == About 200,000 tonnes of tetrahydrofuran are produced annually. The most widely used industrial process involves the acid-catalyzed dehydration of 1,4-butanediol. Ashland/ISP is one of the biggest producers of this chemical route. The method is similar to the production of diethyl ether from ethanol. The butanediol is derived from condensation of acetylene with formaldehyde followed by hydrogenation. DuPont developed a process, for producing THF by oxidizing n-butane to crude maleic anhydride, followed by catalytic hydrogenation. A third major industrial route entails hydroformylation of allyl alcohol followed by hydrogenation to 1,4-butanediol.
Argiopine: contains 2,4-dihydroxyphenylacetic acid. It is also named Arg-636. Argiopinines: (4-hydroxyindol-3-yl) acetic acid is carried as the chromophore. These molecules are: Arg-630, Arg-658, Arg-659, Arg-744, Arg-759. Pseudoargiopinines: They contain a (indol-3-yl) acetic acid. This group is composed of: Arg-373, Arg-728, Arg-743.
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.